Level B· Emerging clinical evidence with positive signalsClinical TrialPubMedOpen access

A prospective single-arm study on the effects of repeated intravenous infusions of canine adipose-derived mesenchymal stromal cells in dogs with chronic inflammatory enteropathy.

Yasumura Y., Teshima T., Michishita M., Suzuki R., Matsumoto H.

Clinical Trial on Systemic / IV, published in Stem Cell Res Ther (2025) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Stem Cell Res Ther (2025)
Country
England
Reported sample size
—
Source database
PubMed
PMID
41327382
PMCID
PMC12777331
DOI
10.1186/s13287-025-04842-0

Abstract (original English)

Background Mesenchymal stromal cells (MSCs) are a promising cell source for the treatment of dogs with refractory chronic inflammatory enteropathy (CIE). Although several clinical trials have reported the beneficial effects of MSCs for CIE, all previous studies were conducted by the same research group using a single intravenous infusion protocol. Because most intravenously infused MSCs rapidly disappear from the body, repeated infusions of these cells at regular intervals may prolong the short-term effects of MSCs. This study evaluated the short-term clinical outcomes and safety of a treatment regimen including repeated intravenous infusions of allogeneic MSCs in dogs with refractory CIE. Methods Dogs with refractory CIE received repeated intravenous infusions of 2 × 10 6 cells/kg of allogeneic adipose-derived MSCs according to the following protocol: twice weekly at 3-4 day intervals for the first 2 weeks, once weekly for the next 2 weeks, and once every 2 weeks during the subsequent 4 weeks. We measured the Clinical Inflammatory Bowel Disease Activity Index (CIBDAI), Canine Chronic Enteropathy Activity Index (CCECAI), serum albumin concentration, and prednisolone dosage in each dog 30 days before treatment, immediately before treatment, and at 2 weeks, 1 month, and 2 months after the start of treatment. The primary endpoint of the treatment response was clinical remission ba

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
AnimalsDogsMesenchymal Stem Cell TransplantationMesenchymal Stem CellsMaleInfusions, IntravenousFemaleDog DiseasesAdipose TissueProspective Studies

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research